- Home
- QCLS vs TPST Comparison
QCLS vs TPST Comparison
Compare QCLS & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QCLS | TPST |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 15.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | QCLS | TPST |
|---|---|---|
| Price | $4.58 | $2.78 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | ★ 1.7M | 76.9K |
| Earning Date | 11-19-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $2.75 |
| 52 Week High | $152.00 | $13.65 |
Technical Indicators
Market Signals| Indicator | QCLS | TPST |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 27.88 |
| Support Level | N/A | $2.80 |
| Resistance Level | N/A | $3.04 |
| Average True Range (ATR) | 0.00 | 0.16 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 0.00 | 8.29 |
Price Performance
Historical ComparisonAbout QCLS Q/C Technologies Inc.
Q/C Technologies Inc is engaged in building blockchain infrastructure that is faster and more energy-efficient. The company uses laser-based processors inspired by quantum technology that can solve complex problems at the speed of light. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.